Tirzepatide is studied as a dual agonist — a single molecule that activates two incretin receptors, GIP and GLP-1. In research models, that dual engagement is the central object of study.
The two receptors
GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are incretin receptors involved in glucose-regulation and energy-balance signaling. Tirzepatide binds both, and researchers investigate how simultaneous activation influences downstream pathways compared with single-receptor agonists such as semaglutide.
What researchers examine
- Receptor-binding affinity and selectivity at GIP vs GLP-1
- Downstream signaling (e.g. cAMP pathways) in cell models
- Comparative effects vs single-agonist controls — see semaglutide vs tirzepatide
Product page: Tirzepatide research vials.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.